Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Background: Comprehensive description of ketamine's molecular binding profile becomes increasingly pressing as use in real-life patient cohorts widens. Animal studies attribute a significant role in the substance's antidepressant effects to the serotonergic system. The serotonin transporter is a highly relevant target in this context, because it is central to depressive pathophysiology and treatment. This is, to our knowledge, the first study investigating ketamine's serotonin transporter binding in vivo in humans. Methods: Twelve healthy subjects were assessed twice using [11C]DASB positron emission tomography. A total of 0.50 mg/kg bodyweight ketamine was administered once i.v. prior to the second positron emission tomography scan. Ketamine plasma levels were determined during positron emission tomography. Serotonin transporter nondisplaceable binding potential was computed using a reference region model, and occupancy was calculated for 4 serotonin transporter-rich regions (caudate, putamen, thalamus, midbrain) and a whole-brain region of interest. Results: After administration of the routine antidepressant dose, ketamine showed <10% occupancy of the serotonin transporter, which is within the test-retest variability of [11C]DASB. A positive correlation between ketamine plasma levels and occupancy was shown. Conclusions: Measurable occupancy of the serotonin transporter was not detectable after administration of an antidepressant dose of ketamine. This might suggest that ketamine binding of the serotonin transporter is unlikely to be a primary antidepressant mechanism at routine antidepressant doses, as substances that facilitate antidepressant effects via serotonin transporter binding (e.g., selective serotonin reuptake inhibitors) show 70% to 80% occupancy. Administration of high-dose ketamine is widening. Based on the positive relationship we find between ketamine plasma levels and occupancy, there is a need for investigation of ketamine's serotonin transporter binding at higher doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. (a) No measurable occupancy of the serotonin transporter (SERT) after 0.50 mg/kg bodyweight ketamine. [11C]DASB nondisplaceable binding potential (BPND) decreased numerically from positron emission tomography (PET) 1 (left, before ketamine application) to PET 2 (right, after application of the standard antidepressant dose of 0.50 mg/kg bodyweight ketamine) in the caudate, putamen, and thalamus. Mean occupancy values ± SD of the SERT were 5.86±21.88, 2.70±13.76, and 1.11±23.27, respectively. Results were interpreted as a lack of measurable binding, because occupancy values are within [11C]DASB test-retest variability (Kranz et al., 2015) (see supplement). Color bar represents [11C]DASB BPND. Slices at z=10 (caudate), z=6 (putamen), and z=12 (thalamus). For [11C]DASB BPND and occupancy values see Table 1. (b) Correlation between ketamine plasma levels and SERT occupancy. Ketamine plasma levels assessed after ketamine administration during PET correlated with SERT occupancy within the caudate and putamen (caudate 20 min: P=.042; 30 min: P=.018; putamen 30 min: P=.031, all uncorr., min indicate time after start of PET measurement). Though the correlations are influenced by outliers, these findings might suggest that ketamine may bind the SERT when levels are higher, for example, when ketamine is administered at higher doses or depending on differences in metabolism (Zarate et al., 2012; Zhao et al., 2012). Correlation analyses with ketamine plasma levels drawn 30 minutes after PET start are depicted. Correlations may be significant at this time point, as ketamine kinetics are known to switch from the distribution to elimination phase around this time (Hijazi et al., 2003). *Indicates statistical significance of correlations (P<.05, uncorrected). For occupancy values and ketamine plasma levels, see Tables 1 and 2.](https://figures.cochat.ai/paper-figures/b71e4f80170d4f9788e19a4b402fcca0/assessment-of-ketamine-binding-of-the-serotonin-transporter-in-humans-with-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This study did not observe significant occupancy of ketamine at SERT in the caudate, putamen, thalamus, and whole brain ROIs.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Spies et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“, 2015) and raised questions as to how often the substance should be applied (Murrough et al., 2013) and in combination with what other potentiating or effect-stabilizing treatments (Chiu et al.”
BackgroundIchise, M., Liow, J.-S., Lu, J.-Q., Takano, A., Model, K., Toyama, H., Suhara, T., Suzuki, K., Innis, R. B., & Carson, R. E. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000085441.37552.ca · Cited by 650
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468 · cited 1×
“As an NMDA receptor antagonist (Lener et al., 2016), ketamine modulates the glutamatergic system, though it has also been shown to effect dopaminergic (Li et al.”
BackgroundKapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459 · cited 1×
“It has, however, been suggested that ketamine may bind 5-HT2 receptors (Kapur and Seeman, 2002; Waelbers et al., 2013).”
Background
Cited by
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066651 · Cited by 120
The influence of ketamine on drug discovery in depression
Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.007 · Cited by 75
“Ketamine also inhibits the reuptake of serotonin, dopamine and norepinephrine [47], although a recent positron emission tomography (PET) study found no evidence that ketamine treatment alters serotonin transporter occupancy [48].”
BackgroundJohnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Lavender, E., Hirasawa-Fujita, M., & Domino, E. F. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112631 · Cited by 58
Using genetic drug-target networks to develop new drug hypotheses for major depressive disorder
Gaspar, H. A., Gerring, Z. F., Hübel, C., Middeldorp, C. M., Derks, E. M., & Breen, G. D. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0451-4 · Cited by 54
The role of serotonin neurotransmission in rapid antidepressant actions
Pehrson, A. L., Roberts, D., Khawaja, A., & McNair, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06098-5 · Cited by 37
Bowman, M. A., Vitela, M., Clarke, K. M., Koek, W., & Daws, L. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207581 · Cited by 33
“More recently, Spies and colleagues [59] used PET imaging in humans to examine the effects of 0.”
BackgroundStorm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 33
Electrochemical and biosensor techniques to monitor neurotransmitter changes with depression
Dunham, K. E., & Venton, B. J. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05136-9 · Cited by 34
Chaki, S., & Fukumoto, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061270 · Cited by 30
Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites
Ago, Y., Yokoyama, R., Asano, S., & Hashimoto, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109313 · Cited by 26
Rapid and Sustained Restoration of Astrocytic Functions by Ketamine in Depression Model Mice
Ma, X., Yang, S., Zhang, Z., Liu, L., Shi, W., Yang, S., Li, S., Cai, X., & Zhou, Q. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.03.068 · Cited by 21
Vanicek, T., Unterholzner, J., Lanzenberger, R. R., Naderi‐Heiden, A., Kasper, S. F., & Praschak-Rieder, N. (2022) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2031287 · Cited by 19
Self-citationKojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 13
Colla, M., Scheerer, H., Weidt, S., Seifritz, E., & Kronenberg, G. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.759466 · Cited by 13
Ready for a “breakthrough” with ketamine? A look at recent pharmacological insights!
Himmelseher, S., & Kochs, E. F. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001017 · Cited by 10
Dunham, K. E., Khaled, K. H., Weizman, L., & Venton, B. J. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16070 · Cited by 9
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Self-citationDeka, A., Joseph, E., Sharma, N., Berhanu, T., & Kaplan, J. (2024) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000787 · Cited by 5
Inhibition of SERT and NMDAR synergistically confers rapid antidepressant effects of ketamine
Luo, H., Chen, M., Ning, Y., Ren, L., Lu, Y., Sun, J., Zhu, X., Ran, M., Guo, J., Lu, C., et al. (2025) · National Science Review · doi:10.1093/nsr/nwaf367 · Cited by 5
KETAMIR-2, a new molecular entity and novel ketamine analog
Angel, I., Perelroizen, R., Deffains, W., Adraoui, F. W., Pichinuk, E., & Aminov, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1606976 · Cited by 4
Wang, X., Wang, T., Fan, X., Zhang, Z., Wang, Y., & Li, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01965 · Cited by 4
Angel, I., Perelroizen, R., Pichinuk, E., & Aminov, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1650926 · Cited by 3
Handschuh, P. A., Konadu, M. E., Spurny‐Dworak, B., Silberbauer, L., Murgaš, M., & Lanzenberger, R. R. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_18 · Cited by 2
Self-citationAnaesthesia and PET of the Brain
Absalom, A. R., & Ram, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_44 · Cited by 2
Liu, Y., Hung, C., Potenza, M. N., Chou, K., Lee, P., Huang, C., Li, C. R., Lee, T. S., & Lin, C. (2026) · Addiction · doi:10.1111/add.70331 · Cited by 1
Pharmacological and Surgical Approaches to Pain
Marchand, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-56541-0_6 · Cited by 1
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Human in vivo assessment of ketamine binding of the serotonin transporter—follow up at a higher dose
Schlosser, G., Murgaš, M., Godbersen, G. M., Reichel, S., Silberbauer, L., Nics, L., Winkler, D., Stimpfl, T., Hacker, M., Kasper, S. F., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1651016
Self-citationMeðferðir við vímuefnavanda : gætu hugvíkkandi efni verið ákjósanlegur valkostur í meðferðum?
Víðisdóttir, H. S., & Þórsdóttir, G. B. (2021) · Skemman
Kasper, S., Kraus, C., & Lanzenberger, R. (2017) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Self-citationMatheson, G. J., Lundberg, J., Gärde, M., Veldman, E. R., Tateno, A., Ekman, C., Arakawa, R., Knudsen, G. M., Okubo, Y., Ogden, R. T., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03704-2
Psychedelics and the thalamocortical system: A scoping review
Villalba, S., Christensen, A. M., Costanzo, L. D., Torterolo, P., Carrera, I., Urbano, F. J., & Bisagno, V. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174232
Saelens, J., Stadler, F., Forschauer, V., Baldermann, J. C., Henter, I. D., Zarate, C. A., & Kraus, C. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04480-x
Metadata
- Authors
- Spies, M., James, G. M., Berroterán-Infante, N., Ibeschitz, H., Kranz, G. S., Unterholzner, J., Godbersen, M., Gryglewski, G., Hienert, M., Jungwirth, J., Pichler, V., Reiter, B., Silberbauer, L., Winkler, D., Mitterhauser, M., Stimpfl, T., Hacker, M., Kasper, S., & Lanzenberger, R.
- Affiliations
- Ludwig Boltzmann Institute Applied Diagnostics (AT)
- Corresponding author
- Lanzenberger, Rupert
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-16
- Volume
- 21
- Issue
- 2
- Pages
- 145-153
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5793827
- OpenAlex
- W2765280907
- Cited by
- 34
- References
- 61
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 3
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (23741)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, serotonin transporter, [11C]DASB, antidepressant mechanism, depression, caudate nucleus, putamen, thalamus, midbrain
- MeSH terms
- Adult, Aniline Compounds, Antidepressive Agents, Humans, Ketamine, Male, Mesencephalon, Sulfides, Thalamus, Neostriatum, Serotonin Agents, Positron-Emission Tomography, Serotonin Plasma Membrane Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.